COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Sep 9, 2021

Calypso Biotech Announces First Patient With Celiac Disease Dosed in anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 Phase 1b Trial, and Extension of Series A to €28M

Jun 18, 2020

Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing USA - English France - Français Deutschland - Deutsch España - español

Feb 19, 2019

AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002 USA - English España - español France - Français Deutschland - Deutsch

Jun 5, 2018

Global Celiac Disease Treatment Market 2018-2023: Major Players Profiled are Biopharmaceuticals, Calypso Biotech, Cour Pharmaceuticals, Doctor Falk Pharmaceuticals, and Glenmark Pharmaceuticals

Aug 29, 2016

Global Interleukin 15 (IL15) Pipeline Review 2016 Featuring Amgen, Calypso Biotech and Digna Biotech - Research and Markets

For More Press Releases

---